Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells
Open Access
- 1 January 2014
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (24) , 7914-25
Abstract
To study if three clinically available small molecule kinase inhibitors (SMI), erlotinib, sunitinib and sorafenib, exert antifibrogenic effects on pancreatic stellate cells (PSC) and analyze the basis of their action. Cultured rat PSC were exposed to SMI. Cell proliferation and viability were assessed employing 5-bromo-2'-deoxyuridine incorporation assay and flow cytometry, respectively. 2-Deoxy-2-[(18)F] fluoroglucose ((18)F-FDG) uptake was measured to study metabolic activity. Exhibition of the myofibroblastic PSC phenotype was monitored by immunofluorescence analysis of α-smooth muscle actin (α-SMA) expression. Levels of mRNA were determined by real-time PCR, while protein expression and phosphorylation were analyzed by immunoblotting. Transforming growth factor-β1 (TGF-β1) levels in culture supernatants were quantified by ELISA. All three SMI inhibited cell proliferation and (18)F-FDG uptake in a dose-dependent manner and without significant cytotoxic effects. Furthermore, additive effects of the drugs were observed. Immunoblot analysis showed that sorafenib and sunitib, but not erlotinib, efficiently blocked activation of the AKT pathway, while all three drugs displayed little effect on phosphorylation of ERK1/2. Cells treated with sorafenib or sunitinib expressed less interleukin-6 mRNA as well as less collagen type 1 mRNA and protein. Sorafenib was the only drug that also upregulated the expression of matrix metalloproteinase-2 and reduced the secretion of TGF-β1 protein. All three drugs showed insignificant or discordant effects on the mRNA and protein levels of α-SMA. The tested SMI, especially sorafenib, exert inhibitory effects on activated PSC, which should be further evaluated in preclinical studies.Keywords
This publication has 51 references indexed in Scilit:
- Molecularly Targeted Therapies in Metastatic Pancreatic CancerPancreas, 2013
- PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.2010
- Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and EvidenceCurrent Oncology, 2010
- Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling PathwaysMolecular Cancer Research, 2010
- Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer CellsCancer Research, 2008
- Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 2007
- Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal AdenocarcinomaClinical Cancer Research, 2004
- Pancreatic stellate cell migration: role of the phosphatidylinositol 3-kinase (PI3-kinase) pathwayBiochemical Pharmacology, 2004
- Identification, culture, and characterization of pancreatic stellate cells in rats and humansGastroenterology, 1998
- Periacinar stellate shaped cells in rat pancreas: identification, isolation, and cultureGut, 1998